Home > Business > PTI > Report

Ranbaxy gets US FDA nod for drug

March 15, 2004 18:29 IST

Ranbaxy Laboratories on Monday said it has received tentative approval from the United States Food and Drug Administration to manufacture and market anti-hypertension drug Quinapril Hydrochloride in the US.

Ranbaxy Pharmaceuticals has received the tentative nod to market the drug in tablets of 5 mg, 10 mg, 20 mg and 40 mg dosages, a company statement said in New Delhi.

Quinapril Hydrochloride has a market size of $632.2 million with Accupril dominating the market with sales of $589 million.

Besides the treatment of hypertension, the drug is also prescribed in the management of heart failure.

Ranbaxy sales and marketing vice-president Jim Meehan said a final approval of the drug will add Quinapril Hydrochloride tablets to "our product portfolio of affordable generic alternatives."

"This product offering in the cardio-vascular class of medications will provide benefits to the US healthcare system, prescribers and patients," he added.


Article Tools
Email this article
Print this article
Write us a letter
Discuss this article



Related Stories


Ranbaxy launches Visclair in UK

Can Indian pharma survive?

Ranbaxy eyes Russian mart



People Who Read This Also Read


Tata Motors plans Rs 60 bn capex

Govt clears FDI worth Rs 530 cr

Govt beats selloff target








© Copyright 2003 PTI. All rights reserved. Republication or redistribution of PTI content, including by framing or similar means, is expressly prohibited without the prior written consent.











Copyright © 2004 rediff.com India Limited. All Rights Reserved.